
Sign up to save your podcasts
Or
Sam Altman is backing Merge Labs, a new brain-computer interface venture exploring a gene therapy approach to connect human brains with AI. The company is considering genetically modifying brain cells to respond to ultrasound, enabling a less invasive implant system. Merge is currently raising $250 million at an $850 million valuation, with major backing expected from OpenAI’s venture arm. This move positions Altman in direct competition with Elon Musk’s Neuralink, which uses electrode-based implants. Merge’s approach combines sonogenetics and embedded ultrasound hardware, aiming for high-bandwidth communication between thought and AI systems. Altman is co-founding the project but won’t take a day-to-day role or personally invest.
3.6
247247 ratings
Sam Altman is backing Merge Labs, a new brain-computer interface venture exploring a gene therapy approach to connect human brains with AI. The company is considering genetically modifying brain cells to respond to ultrasound, enabling a less invasive implant system. Merge is currently raising $250 million at an $850 million valuation, with major backing expected from OpenAI’s venture arm. This move positions Altman in direct competition with Elon Musk’s Neuralink, which uses electrode-based implants. Merge’s approach combines sonogenetics and embedded ultrasound hardware, aiming for high-bandwidth communication between thought and AI systems. Altman is co-founding the project but won’t take a day-to-day role or personally invest.
4,990 Listeners
227,868 Listeners
32 Listeners
341 Listeners
4,707 Listeners
395 Listeners
17,104 Listeners
9,800 Listeners
4,280 Listeners
61 Listeners
534 Listeners
149 Listeners
555 Listeners
1 Listeners
148 Listeners
16,923 Listeners
25 Listeners